Retatrutide side effects and results in studies
Where a cited study reported on tolerability, its wording is carried over unchanged below. Human work of this size does not establish a safety profile.
Adverse events reported
| Event | As reported | Source |
|---|---|---|
| The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate. | Human | Jastreboff AM et al. |
| Discontinuation for adverse events was 2–5% with retatrutide and 0% with placebo. | Human | Bajaj HS et al. |
| Treatment-emergent adverse events were reported by 63% of participants on LY3437943, 60% on dulaglutide and 54% on placebo, with gastrointestinal disorders the most frequent. | Human | Urva S et al. |
Outcomes measured
No outcome data are tabulated yet.
What the studies don't show
None of it establishes safety outside the conditions each trial ran under. Knowing the vial holds what the label says is not the same as knowing the compound does anything.